|  Help  |  About  |  Contact Us

Publication : Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

First Author  Zingg D Year  2022
Journal  Nature Volume  608
Issue  7923 Pages  609-617
PubMed ID  35948633 Mgi Jnum  J:339928
Mgi Id  MGI:7525123 Doi  10.1038/s41586-022-05066-5
Citation  Zingg D, et al. (2022) Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature 608(7923):609-617
abstractText  Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer(1). However, clinical responses to FGFR inhibitors have remained variable(1-9), emphasizing the need to better understand which FGFR2 alterations are oncogenic and therapeutically targetable. Here we apply transposon-based screening(10,11) and tumour modelling in mice(12,13), and find that the truncation of exon 18 (E18) of Fgfr2 is a potent driver mutation. Human oncogenomic datasets revealed a diverse set of FGFR2 alterations, including rearrangements, E1-E17 partial amplifications, and E18 nonsense and frameshift mutations, each causing the transcription of E18-truncated FGFR2 (FGFR2(DeltaE18)). Functional in vitro and in vivo examination of a compendium of FGFR2(DeltaE18) and full-length variants pinpointed FGFR2-E18 truncation as single-driver alteration in cancer. By contrast, the oncogenic competence of FGFR2 full-length amplifications depended on a distinct landscape of cooperating driver genes. This suggests that genomic alterations that generate stable FGFR2(DeltaE18) variants are actionable therapeutic targets, which we confirmed in preclinical mouse and human tumour models, and in a clinical trial. We propose that cancers containing any FGFR2 variant with a truncated E18 should be considered for FGFR-targeted therapies.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

1 Bio Entities

0 Expression